icon caret-left icon caret-right instagram pinterest linkedin facebook twitter goodreads question-circle facebook circle twitter circle linkedin circle instagram circle goodreads circle pinterest circle

Genetic Linkage

How snake venom and a smoking cessation drug inspired a nasal spray that blocks COVID

A simple nasal spray that stops SARS-CoV-2 in its tracks? 


That could block the coronavirus in the nose, before it can travel down to the lungs or be coughed onto another person, perhaps becoming a powerful partner to vaccines and therapeutics, and easy to administer, store, and ship.


It "could allow us to reduce transmission and be able to have a quick response to outbreaks in certain areas of the world," said Jeffrey Nau, CEO of Oyster Point Pharma, based in Princeton NJ. The company recently announced repurposing of the smoking-cessation pill Chantix™ (varenacline), as well as a second molecule in the same class, simpinicline, each as nasal sprays against COVID. The FDA approved Chantix, a Pfizer product, in 2006. Today nearly 400 clinical trials are exploring other uses.


To continue reading, go to Genetic Literacy Project, where this post first appeared.

Be the first to comment